새우 질병 진단 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2031년) - 제품, 기술, 등급, 용도, 최종 사용자 및 지역별

Shrimp Disease Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)

US $ 4,995 ￦ 7,030,000

Unprintable PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 텍스트의 Copy&Paste도 불가능합니다.

US $ 8,495 ￦ 11,956,000

Unprintable PDF & Excel (Multi User License upto 5 users)

PDF 및 Excel 보고서를 동일 사업장에서 5명까지 이용할 수 있는 라이선스입니다. 텍스트는 Copy & Paste 가능하지만, 인쇄는 불가능합니다.

US $ 10,600 ￦ 14,919,000

Printable PDF & Excel (Enterprise License above 5 users)

PDF 및 Excel 보고서를 동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용자수는 5명 이상이며 제한은 없습니다. Copy & Paste 및 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 새우 질병 진단 시장 규모는 2024년 약 4억 8,400만 달러의 매출을 기록할 것으로 예상되며, 2031년 말에는 약 8억 달러에 달할 것으로 예상됩니다. 이 호황을 누리고 있는 이 분야는 새우에 대한 세계 수요 급증에 힘입어 동물 진단 산업의 중요한 구성 요소입니다.

세계 수산물 소비의 주식인 새우에 대한 수요 증가는 새우 질병 진단 시장 확대의 원동력이 되고 있습니다. 새우 양식은 인간의 식량과 영양 공급에 필수적이며, 이러한 수요는 해양 및 담수 새우 생산으로 인해 발생합니다. 새우 질병 진단은 새우 개체군의 건강을 유지하고, 전염병의 확산을 방지하고, 새우 양식의 지속가능성을 보호하는 데 매우 중요한 역할을 합니다.

특히 흰점 증후군(WSS)과 같이 현재 치료법이 제한적인 위협의 경우 조기 발견이 중요하며, PCR 및 DNA 혼성화와 같은 고급 진단 도구는 새우 양식의 생물 보안을 강화하고 최상의 관리 방법을 추진하는 데 도움이 되고 있습니다.

유망한 성장 궤도에도 불구하고 새우 질병 진단 시장은 몇 가지 문제에 직면해 있습니다. 실험실에서 집중적인 질병 검출은 비용과 시간이 많이 들며, 전문 시설과 숙련된 인력이 필요합니다. 일부 지역에서는 새우 질병 진단에 대한 규제 프레임워크가 아직 개발 중이어서 시장 성장을 저해할 수 있습니다.

또한, 아시아 등 개발도상국에서는 검역, 감시 및 질병 식별 능력을 강화해야 하며, 이는 살아있는 동물의 수입으로 인한 질병 전파 위험을 줄이기 위해 필수적입니다. 일부 지역에서는 이미 국내 갑각류 개체군을 보호하고 지속 가능한 관행을 보장하기 위해 관리 규제를 시행하고 있습니다.

이 보고서는 세계의 새우 질병 진단시장에 대해 조사했으며, 시장 개요와 함께 제품/기술/등급/용도/최종 사용자 및 지역별 동향, 시장 진출기업의 경쟁 동향 등의 정보를 제공합니다.

목차

제1장 주요 요약

제2장 시장 개요

• 시장 정의와 세분화
• 시장 역학
• 밸류체인 분석
• Porter의 Five Forces 분석
• COVID-19의 영향 분석
• 우크라이나와 러시아 분쟁의 영향
• 경제 개요
• PESTLE 분석

제3장 세계의 새우 질병 진단 시장 전망, 2018년-2031년

• 세계의 새우 질병 진단 시장 전망, 시약별, 금액, 2018년-2031년
• 세계의 새우 질병 진단 시장 전망, 질환별, 금액, 2018년-2031년
• 세계의 새우 질병 진단 시장 전망, 최종사용자별, 금액, 2018년-2031년
• 세계의 새우 질병 진단 시장 전망, 지역별, 금액, 2018년-2031년

제4장 북미의 새우 질병 진단 시장 전망, 2018년-2031년

제5장 유럽의 새우 질병 진단 시장 전망, 2018년-2031년

제6장 아시아태평양의 새우 질병 진단 시장 전망, 2018년-2031년

제7장 라틴아메리카의 새우 질병 진단 시장 전망, 2018년-2031년

제8장 중동 및 아프리카의 새우 질병 진단 시장 전망, 2018년-2031년

제9장 경쟁 구도

• 질병 vs. 시약 히트맵
• 기업의 시장 점유율 분석, 2023년
• 경쟁력 대시보드
• 기업 개요
  • HiMedia Laboratories
  • Speedy Assay Sdn Bhd
  • REAGEN LLC
  • FUJIKURA KASEI CO., LTD.
  • GeneReach Biotechnology Corp.
  • Thermo Fisher Scientific
  • Lab - Ind Resource Sdn Bhd.
  • SUREBIO
  • Auro Biotechnologies Pvt. Ltd.

제10장 부록

LSH

영문 목차

영문목차

The global Shrimp Disease Diagnostics Market is poised for remarkable growth, with revenues reaching approximately US$ 484.0 Million in 2024 and a projected valuation of about US$ 800.0 Million by the end of 2031, according to recent report by Fairfield Market Research. This thriving sector is a vital component of the animal diagnostics industry, propelled by the surging global demand for shrimp.

Biosecurity for Healthy Shrimps and Disease Prevention

The escalating demand for shrimp, a staple in global seafood consumption, has been a driving force behind the expansion of the shrimp disease diagnostics market. Shrimp aquaculture is crucial for human food and nutrition supply, and this demand is driven by both marine and freshwater shrimp production. Shrimp disease diagnostics play a pivotal role in maintaining the health of shrimp populations, preventing the spread of infectious diseases, and safeguarding the sustainability of shrimp farming.

In particular, the market has witnessed an increased focus on early disease detection, especially for threats like White Spot Syndrome (WSS), where therapeutic options are currently limited. Advanced diagnostic tools, such as PCR and DNA hybridization, have been instrumental in enhancing biosecurity and promoting best management practices in shrimp farming.

Challenges and Opportunities

Despite its promising growth trajectory, the shrimp disease diagnostics market faces several challenges. The centralized nature of disease detection in laboratories can be costly and time-consuming, demanding specialized facilities and skilled personnel. Regulatory frameworks for shrimp disease diagnostics are still evolving in some regions, potentially impeding market growth.

In addition, the need for enhanced capacity in developing nations, such as those in Asia, to carry out quarantine, surveillance, and disease identification is critical to mitigate disease transmission risks associated with live animal importation. Some regions have already implemented management regulations to protect domestic crustacean populations and ensure sustainable practices.

Country-wise Insights

United States: The U.S. market is set to expand the global market due to its access to advanced molecular diagnostic tools. Factors such as a higher prevalence of infections, rising healthcare expenditure, efficient healthcare infrastructures, and skilled laboratory technicians are contributing to market growth. Collaborations within the aquaculture industry are furthering the focus on health management and disease prevention.

China: As the world's largest consumer of seafood, China is a dominant player in shrimp farming and disease diagnostics. Government regulations ensure seafood safety and quality, prompting an increased demand for disease diagnostics to comply with these standards. Innovations like real-time PCR and ELISA assays have enhanced diagnosis accuracy and speed, further driving adoption.

Germany: Germany's significant seafood market and rising shrimp demand have led to a greater need for effective disease diagnostics. The presence of key market players in the shrimp disease diagnostics market has increased product availability and competition. The incidence of shrimp diseases in the region, including WSSV, YHV, and TSV, has also surged.

Competitive Landscape

Key players in the shrimp disease diagnostics market are actively collaborating with ISO-accredited government laboratories and universities to develop and commercialize innovative diagnostic products. These collaborations aim to leverage advanced technologies for manufacturing genetic diagnostics tools.

Notable companies in the market include:

• HiMedia Laboratories
• Speedy Assay Sdn Bhd
• REAGEN LLC
• FUJIKURA KASEI CO., LTD.
• GeneReach Biotechnology Corp.
• Thermo Fisher Scientific
• Lab - Ind Resource Sdn Bhd.
• SUREBIO
• Auro Biotechnologies Pvt. Ltd.

Key Segments Covered in Shrimp disease diagnostics Industry Research

Reagent:

• Rapid Testing Kits
• Assay Based Kits

Disease:

• WSSV (White Spot Syndrome Virus)
• TSV (Taura Syndrome Virus)
• YHV/GAV (Yellow Head/Gill Associated Virus)
• IHHNV (Infectious Hypodermal and Hematopoietic Virus)
• HPV (Hepatopancreatic Parvovirus)
• MBV (Monodon Baculovirus)
• IMNV (Infectious Myonecrosis Virus)
• NHP-B (Necrotising Hepatopancreatitis Bacteria)
• MoV (Mourilyan Virus)
• Early Mortality Syndrome (EMS)

End User:

• Fisheries
• Aquaculture Laboratories
• Marine Laboratories
• Education and Research Institutes
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

Table of Contents

1. Executive Summary

• 1.1. Global Shrimp Disease Diagnostics Market Snapshot
• 1.2. Future Projections
• 1.3. Key Market Trends
• 1.4. Regional Snapshot, by Value, 2023
• 1.5. Analyst Recommendations

2. Market Overview

• 2.1. Market Definitions and Segmentations
• 2.2. Market Dynamics
  • 2.2.1. Drivers
  • 2.2.2. Restraints
  • 2.2.3. Market Opportunities
• 2.3. Value Chain Analysis
• 2.4. Porter's Five Forces Analysis
• 2.5. COVID-19 Impact Analysis
  • 2.5.1. Supply
  • 2.5.2. Demand
• 2.6. Impact of Ukraine-Russia Conflict
• 2.7. Economic Overview
  • 2.7.1. World Economic Projections
• 2.8. PESTLE Analysis

3. Global Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

• 3.1. Global Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
  • 3.1.1. Key Highlights
    • 3.1.1.1. Rapid Testing Kits
    • 3.1.1.2. Assay Based Kits
• 3.2. Global Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
  • 3.2.1. Key Highlights
    • 3.2.1.1. WSSV (White Spot Syndrome Virus)
    • 3.2.1.2. TSV (Taura Syndrome Virus)
    • 3.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
    • 3.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
    • 3.2.1.5. HPV (Hepatopancreatic Parvovirus)
    • 3.2.1.6. MBV (Monodon Baculovirus)
    • 3.2.1.7. IMNV (Infectious Myonecrosis Virus)
    • 3.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
    • 3.2.1.9. MoV (Mourilyan Virus)
    • 3.2.1.10. Early Mortality Syndrome (EMS)
• 3.3. Global Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
  • 3.3.1. Key Highlights
    • 3.3.1.1. Fisheries
    • 3.3.1.2. Aquaculture Laboratories
    • 3.3.1.3. Marine Laboratories
    • 3.3.1.4. Education and Research Institutes
    • 3.3.1.5. Others
• 3.4. Global Shrimp Disease Diagnostics Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
  • 3.4.1. Key Highlights
    • 3.4.1.1. North America
    • 3.4.1.2. Europe
    • 3.4.1.3. Asia Pacific
    • 3.4.1.4. Latin America
    • 3.4.1.5. Middle East & Africa

4. North America Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

• 4.1. North America Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
  • 4.1.1. Key Highlights
    • 4.1.1.1. Rapid Testing Kits
    • 4.1.1.2. Assay Based Kits
• 4.2. North America Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
  • 4.2.1. Key Highlights
    • 4.2.1.1. WSSV (White Spot Syndrome Virus)
    • 4.2.1.2. TSV (Taura Syndrome Virus)
    • 4.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
    • 4.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
    • 4.2.1.5. HPV (Hepatopancreatic Parvovirus)
    • 4.2.1.6. MBV (Monodon Baculovirus)
    • 4.2.1.7. IMNV (Infectious Myonecrosis Virus)
    • 4.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
    • 4.2.1.9. MoV (Mourilyan Virus)
    • 4.2.1.10. Early Mortality Syndrome (EMS)
• 4.3. North America Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
  • 4.3.1. Key Highlights
    • 4.3.1.1. Fisheries
    • 4.3.1.2. Aquaculture Laboratories
    • 4.3.1.3. Marine Laboratories
    • 4.3.1.4. Education and Research Institutes
    • 4.3.1.5. Others
• 4.4. North America Shrimp Disease Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 4.4.1. Key Highlights
    • 4.4.1.1. U.S. Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 4.4.1.2. U.S. Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 4.4.1.3. U.S. Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 4.4.1.4. Canada Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 4.4.1.5. Canada Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 4.4.1.6. Canada Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
  • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

• 5.1. Europe Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
  • 5.1.1. Key Highlights
    • 5.1.1.1. Rapid Testing Kits
    • 5.1.1.2. Assay Based Kits
• 5.2. Europe Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
  • 5.2.1. Key Highlights
    • 5.2.1.1. WSSV (White Spot Syndrome Virus)
    • 5.2.1.2. TSV (Taura Syndrome Virus)
    • 5.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
    • 5.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
    • 5.2.1.5. HPV (Hepatopancreatic Parvovirus)
    • 5.2.1.6. MBV (Monodon Baculovirus)
    • 5.2.1.7. IMNV (Infectious Myonecrosis Virus)
    • 5.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
    • 5.2.1.9. MoV (Mourilyan Virus)
    • 5.2.1.10. Early Mortality Syndrome (EMS)
• 5.3. Europe Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
  • 5.3.1. Key Highlights
    • 5.3.1.1. Fisheries
    • 5.3.1.2. Aquaculture Laboratories
    • 5.3.1.3. Marine Laboratories
    • 5.3.1.4. Education and Research Institutes
    • 5.3.1.5. Others
• 5.4. Europe Shrimp Disease Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 5.4.1. Key Highlights
    • 5.4.1.1. Germany Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 5.4.1.2. Germany Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 5.4.1.3. Germany Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.1.4. U.K. Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 5.4.1.5. U.K. Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 5.4.1.6. U.K. Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.1.7. France Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 5.4.1.8. France Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 5.4.1.9. France Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.1.10. Italy Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 5.4.1.11. Italy Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 5.4.1.12. Italy Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.1.13. Turkey Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 5.4.1.14. Turkey Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 5.4.1.15. Turkey Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.1.16. Russia Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 5.4.1.17. Russia Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 5.4.1.18. Russia Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 5.4.1.19. Rest of Europe Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 5.4.1.20. Rest of Europe Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 5.4.1.21. Rest of Europe Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
  • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

• 6.1. Asia Pacific Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
  • 6.1.1. Key Highlights
    • 6.1.1.1. Rapid Testing Kits
    • 6.1.1.2. Assay Based Kits
• 6.2. Asia Pacific Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
  • 6.2.1. Key Highlights
    • 6.2.1.1. WSSV (White Spot Syndrome Virus)
    • 6.2.1.2. TSV (Taura Syndrome Virus)
    • 6.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
    • 6.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
    • 6.2.1.5. HPV (Hepatopancreatic Parvovirus)
    • 6.2.1.6. MBV (Monodon Baculovirus)
    • 6.2.1.7. IMNV (Infectious Myonecrosis Virus)
    • 6.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
    • 6.2.1.9. MoV (Mourilyan Virus)
    • 6.2.1.10. Early Mortality Syndrome (EMS)
• 6.3. Asia Pacific Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
  • 6.3.1. Key Highlights
    • 6.3.1.1. Fisheries
    • 6.3.1.2. Aquaculture Laboratories
    • 6.3.1.3. Marine Laboratories
    • 6.3.1.4. Education and Research Institutes
    • 6.3.1.5. Others
• 6.4. Asia Pacific Shrimp Disease Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 6.4.1. Key Highlights
    • 6.4.1.1. China Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 6.4.1.2. China Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 6.4.1.3. China Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.1.4. Japan Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 6.4.1.5. Japan Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 6.4.1.6. Japan Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.1.7. South Korea Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 6.4.1.8. South Korea Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 6.4.1.9. South Korea Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.1.10. India Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 6.4.1.11. India Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 6.4.1.12. India Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.1.13. Southeast Asia Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 6.4.1.14. Southeast Asia Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 6.4.1.15. Southeast Asia Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 6.4.1.16. Rest of Asia Pacific Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 6.4.1.17. Rest of Asia Pacific Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 6.4.1.18. Rest of Asia Pacific Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
  • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

• 7.1. Latin America Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
  • 7.1.1. Key Highlights
    • 7.1.1.1. Rapid Testing Kits
    • 7.1.1.2. Assay Based Kits
• 7.2. Latin America Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
  • 7.2.1.1. WSSV (White Spot Syndrome Virus)
  • 7.2.1.2. TSV (Taura Syndrome Virus)
  • 7.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
  • 7.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
  • 7.2.1.5. HPV (Hepatopancreatic Parvovirus)
  • 7.2.1.6. MBV (Monodon Baculovirus)
  • 7.2.1.7. IMNV (Infectious Myonecrosis Virus)
  • 7.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
  • 7.2.1.9. MoV (Mourilyan Virus)
  • 7.2.1.10. Early Mortality Syndrome (EMS)
• 7.3. Latin America Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
  • 7.3.1. Key Highlights
    • 7.3.1.1. Fisheries
    • 7.3.1.2. Aquaculture Laboratories
    • 7.3.1.3. Marine Laboratories
    • 7.3.1.4. Education and Research Institutes
    • 7.3.1.5. Others
• 7.4. Latin America Shrimp Disease Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 7.4.1. Key Highlights
    • 7.4.1.1. Brazil Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 7.4.1.2. Brazil Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 7.4.1.3. Brazil Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 7.4.1.4. Mexico Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 7.4.1.5. Mexico Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 7.4.1.6. Mexico Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 7.4.1.7. Argentina Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 7.4.1.8. Argentina Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 7.4.1.9. Argentina Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 7.4.1.10. Rest of Latin America Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 7.4.1.11. Rest of Latin America Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 7.4.1.12. Rest of Latin America Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
  • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Shrimp Disease Diagnostics Market Outlook, 2018 - 2031

• 8.1. Middle East & Africa Shrimp Disease Diagnostics Market Outlook, by Reagent, Value (US$ Bn), 2018 - 2031
  • 8.1.1. Key Highlights
    • 8.1.1.1. Rapid Testing Kits
    • 8.1.1.2. Assay Based Kits
• 8.2. Middle East & Africa Shrimp Disease Diagnostics Market Outlook, by Disease, Value (US$ Bn), 2018 - 2031
  • 8.2.1. Key Highlights
    • 8.2.1.1. WSSV (White Spot Syndrome Virus)
    • 8.2.1.2. TSV (Taura Syndrome Virus)
    • 8.2.1.3. YHV/GAV (Yellow Head/Gill Associated Virus)
    • 8.2.1.4. IHHNV (Infectious Hypodermal and Hematopoietic Virus)
    • 8.2.1.5. HPV (Hepatopancreatic Parvovirus)
    • 8.2.1.6. MBV (Monodon Baculovirus)
    • 8.2.1.7. IMNV (Infectious Myonecrosis Virus)
    • 8.2.1.8. NHP-B (Necrotising Hepatopancreatitis Bacteria)
    • 8.2.1.9. MoV (Mourilyan Virus)
    • 8.2.1.10. Early Mortality Syndrome (EMS)
• 8.3. Middle East & Africa Shrimp Disease Diagnostics Market Outlook, by End User, Value (US$ Bn), 2018 - 2031
  • 8.3.1. Key Highlights
    • 8.3.1.1. Fisheries
    • 8.3.1.2. Aquaculture Laboratories
    • 8.3.1.3. Marine Laboratories
    • 8.3.1.4. Education and Research Institutes
    • 8.3.1.5. Others
• 8.4. Middle East & Africa Shrimp Disease Diagnostics Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
  • 8.4.1. Key Highlights
    • 8.4.1.1. GCC Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 8.4.1.2. GCC Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 8.4.1.3. GCC Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.1.4. South Africa Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 8.4.1.5. South Africa Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 8.4.1.6. South Africa Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.1.7. Egypt Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 8.4.1.8. Egypt Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 8.4.1.9. Egypt Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.1.10. Nigeria Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 8.4.1.11. Nigeria Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 8.4.1.12. Nigeria Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
    • 8.4.1.13. Rest of Middle East & Africa Shrimp Disease Diagnostics Market by Reagent, Value (US$ Bn), 2018 - 2031
    • 8.4.1.14. Rest of Middle East & Africa Shrimp Disease Diagnostics Market by Disease, Value (US$ Bn), 2018 - 2031
    • 8.4.1.15. Rest of Middle East & Africa Shrimp Disease Diagnostics Market by End User, Value (US$ Bn), 2018 - 2031
  • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

• 9.1. Disease vs Reagent Heatmap
• 9.2. Company Market Share Analysis, 2023
• 9.3. Competitive Dashboard
• 9.4. Company Profiles
  • 9.4.1. HiMedia Laboratories
    • 9.4.1.1. Company Overview
    • 9.4.1.2. Product Portfolio
    • 9.4.1.3. Financial Overview
    • 9.4.1.4. Business Strategies and Development
  • 9.4.2. Speedy Assay Sdn Bhd
    • 9.4.2.1. Company Overview
    • 9.4.2.2. Product Portfolio
    • 9.4.2.3. Financial Overview
    • 9.4.2.4. Business Strategies and Development
  • 9.4.3. REAGEN LLC
    • 9.4.3.1. Company Overview
    • 9.4.3.2. Product Portfolio
    • 9.4.3.3. Financial Overview
    • 9.4.3.4. Business Strategies and Development
  • 9.4.4. FUJIKURA KASEI CO., LTD.
    • 9.4.4.1. Company Overview
    • 9.4.4.2. Product Portfolio
    • 9.4.4.3. Financial Overview
    • 9.4.4.4. Business Strategies and Development
  • 9.4.5. GeneReach Biotechnology Corp.
    • 9.4.5.1. Company Overview
    • 9.4.5.2. Product Portfolio
    • 9.4.5.3. Financial Overview
    • 9.4.5.4. Business Strategies and Development
  • 9.4.6. Thermo Fisher Scientific
    • 9.4.6.1. Company Overview
    • 9.4.6.2. Product Portfolio
    • 9.4.6.3. Financial Overview
    • 9.4.6.4. Business Strategies and Development
  • 9.4.7. Lab - Ind Resource Sdn Bhd.
    • 9.4.7.1. Company Overview
    • 9.4.7.2. Product Portfolio
    • 9.4.7.3. Financial Overview
    • 9.4.7.4. Business Strategies and Development
  • 9.4.8. SUREBIO
    • 9.4.8.1. Company Overview
    • 9.4.8.2. Product Portfolio
    • 9.4.8.3. Financial Overview
    • 9.4.8.4. Business Strategies and Development
  • 9.4.9. Auro Biotechnologies Pvt. Ltd.
    • 9.4.9.1. Company Overview
    • 9.4.9.2. Product Portfolio
    • 9.4.9.3. Financial Overview
    • 9.4.9.4. Business Strategies and Development

10. Appendix

• 10.1. Research Methodology
• 10.2. Report Assumptions
• 10.3. Acronyms and Abbreviations

관련자료